Last week, IHH announced that SEBI cleared its stalled open offer for a 26.1 per cent stake in Fortis Healthcare, seven years after the Malaysian firm acquired 31.1 per cent in the Indian hospital chain.
Fortis, partly owned by Malaysia's IHH Healthcare, operates 28 hospitals and manages Gleneagles facilities in India.
The facility, to be built near Gomti Nagar by the Ekana Group, will be positioned as a Centre of Excellence for tertiary care services.
Apollo Hospitals, Fortis Healthcare and Max Healthcare clocked decent growth in revenues despite a disruption to international patient flows
The Fortis Institute of Blood Disorders also integrates paediatric and geriatric care, advanced transplant procedures, and hematopathology expertise, all under one roof, Fortis Healthcare said in a release.
The leading hospital group in partnership with RED.Health plan to reduce the time gap needed by a patient to avail ambulance service in critical emergency hours.
The five entities that received notices are Saubhagya Buildcon, Zolton Properties, Tiger Developers, Torus Buildcon and Rosestar Marketing.
Currently, Fortis operates 27 healthcare facilities and the network comprises approximately 4,300 operational beds and 400 diagnostics centres.
Moneycontrol reported on February 15 that SRL Diagnostics has opened preliminary talks with investment bankers to rope in advisers as the firm looks to launch an IPO to raise around Rs 2,000 crore
The top court issued notice to the standing counsel of the Delhi government and posted the plea for hearing at 1 pm.
Japanese drugmaker Daiichi Sankyo had challenged the Fortis-IHH deal to recover the Rs 3,600 crore arbitration award it had won in a Singapore tribunal against Fortis’ erstwhile promoters
In a case involving Fortis Healthcare, the Securities Appellate Tribunal (SAT) has ordered businessman Malvinder Mohan Singh and Malav Holdings to deposit 50% of the penalty amount levied by markets regulator Sebi within six weeks.
CGHS covers all current and retired central government employees and their families. Their user base is estimated to be around 40 lakh
Even as the third wave of COVID-19 pandemic subsides in India and most cases are reported to be mild, a new study has said that Molnupiravir, granted regulatory approval in the country in December, 2021 can be useful for patients at risk of disease progression.
Dr Ashutosh Raghuvanshi, the Managing Director and CEO of Fortis Healthcare, says case there is any new wave or increase in cases in certain pockets, facilities like telemedicine, E-ICUs will help us provide continuous treatment to the patients.
As the country continues with its lockdown, the step was conceived to continue patient care services without risking the health of patients or doctors
Moneycontrol's Jerome Anthony talks to Corporate Bureau Chief Prince Thomas to find out the top developments in the corporate world.
Does the audit industry consider its responsibility towards a company’s stakeholders while writing out scripted audit reports? There needs to be a systemic focus on improving audit quality standards.
Metropolitan Magistrate Nishant Garg also sent three others, Sunil Godhwani, Kavi Arora and Anil Saxena to judicial custody till October 31.
Fortis has 28.89 percent stake in MSCL, while Mauritius-based CIEL Healthcare holds 58.60, and the remaining is held by other shareholders
On this edition of Digging Deeper with Moneycontrol, we listen to the ballad of the bhais that went bust. The saga of the Singh brothers.
The order came after Daiichi Sankyo filed a contempt plea against Fortis' former promoters Malvinder Singh and Shivinder Singh (Singh brothers)
SEBI has directed the Singh brothers to not associate themselves with the affairs of Fortis Healthcare (FHL) in any manner till further directions
A class action suit is one that allows a large number of people having a common cause of action to jointly file or pursue a litigation.
Former Ranbaxy promoter and Fortis founder Shivinder Singh had alleged about these financial irregularities in his letter earlier this month.